BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 28375829)

  • 1. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
    Tien YC; Yen HH; Chiu YM
    Clin Exp Rheumatol; 2017; 35(5):831-836. PubMed ID: 28375829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
    Chen YM; Chen HH; Huang WN; Chen YH; Hsieh TY; Yang SS; Lan JL; Chen DY
    Int J Rheum Dis; 2019 Jun; 22(6):1145-1151. PubMed ID: 31117160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
    Wang ST; Tseng CW; Hsu CW; Tung CH; Huang KY; Lu MC; Lai NS
    Int J Rheum Dis; 2021 Nov; 24(11):1362-1369. PubMed ID: 34506078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg
    Kuo MH; Tseng CW; Lee CH; Tung CH; Tseng KC; Lai NS
    Sci Rep; 2020 Feb; 10(1):2456. PubMed ID: 32051458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
    Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
    World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J; Li W; Peng X; Tan Z; Tan M; Zhang C; Wang W; Xu Z; Zhou G
    Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.
    Chiu HY; Hui RC; Huang YH; Huang RY; Chen KL; Tsai YC; Lai PJ; Wang TS; Tsai TF
    Acta Derm Venereol; 2018 Oct; 98(9):829-834. PubMed ID: 29972221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
    Chiu YM; Lai MS; Chan KA
    PLoS One; 2018; 13(4):e0196210. PubMed ID: 29694398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
    Kuo MH; Tseng CW; Ko PH; Wang ST; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
    Liver Int; 2024 Feb; 44(2):497-507. PubMed ID: 38010984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.
    Guarino M; Picardi M; Vitello A; Pugliese N; Rea M; Cossiga V; Pane F; Caporaso N; Morisco F
    Ann Hepatol; 2017; 16(2):198-206. PubMed ID: 28233742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
    Tang Z; Li X; Wu S; Liu Y; Qiao Y; Xu D; Li J
    Hepatol Int; 2017 Sep; 11(5):429-433. PubMed ID: 28856548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
    Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
    Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.
    Chen MH; Chen MH; Liu CY; Tsai CY; Huang DF; Lin HY; Lee MH; Huang YH
    J Infect Dis; 2017 Feb; 215(4):566-573. PubMed ID: 28011918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.